New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
10:12 EDTBMY, MDCOThe Medicines Co. and Bristol-Myers' Recothrom collaboration becomes effective
The Medicines Company (MDCO) announced that the global license and two-year collaboration for Recothrom, a recombinant thrombin approved by the FDA for use as a topical hemostat to control non-arterial bleeding during surgical procedures, established with Bristol-Myers Squibb Company (BMY), has become effective. The agreement was first announced in December 2012. The companies have satisfied all required regulatory and closing conditions.
News For MDCO;BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
August 31, 2015
08:10 EDTMDCOThe Medicines Co. price target raised to $45 from $34 at JPMorgan
Subscribe for More Information
07:45 EDTMDCORegeneron should be bought on any pullbacks, says RBC Capital
Subscribe for More Information
07:43 EDTMDCOThe Medicines Co. price target raised to $42 from $32 at Citi
Subscribe for More Information
07:38 EDTMDCOThe Medicines Co. price target raised to $46 from $39 at RBC Capital
Subscribe for More Information
07:31 EDTMDCOThe Medicines Company names Fred Eshelman non-executive chairman
Subscribe for More Information
August 30, 2015
19:07 EDTBMYBristol-Myers partners with QIMR Berghofer for immuno-oncology research
Subscribe for More Information
15:50 EDTMDCOAlnylam, The Medicines Co. say ALN-PCSsc reduces LDL cholesterol as much as 83%
Subscribe for More Information
August 28, 2015
12:59 EDTMDCOFly Watch: Medicines Co., Alnylam rise ahead of cholesterol study presentation
Subscribe for More Information
10:13 EDTMDCOHigh option volume stocks
Subscribe for More Information
10:02 EDTMDCOOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: ADP (ADP) upgraded to Outperform from Market Perform at William Blair... ASML (ASML) upgraded to Buy from Hold at Berenberg... Abercrombie & Fitch (ANF) upgraded on Hollister fundamentals at RBC Capital... Akamai (AKAM) upgraded to Outperform from Market Perform at JMP Securities... Ares Capital (ARCC) upgraded to Outperform from Market Perform at Raymond James... Banco Santander (SAN) upgraded on valuation at Deutsche Bank... CIBC (CM) upgraded to Neutral from Underperform at Credit Suisse... Canon (CAJ) upgraded to Hold from Sell at Deutsche Bank... Citi (C) upgraded to Buy from Neutral at Guggenheim... Ctrip.com (CTRP) upgraded to Buy from Hold at Stifel... El Pollo Loco (LOCO) upgraded at Stifel... Genomic Health (GHDX) upgraded to Market Perform from Underperform at Raymond James... Golar LNG (GLNG) upgraded on valuation, upcoming project completion at Stifel... Habit Restaurants (HABT) upgraded to Buy from Hold at Stifel... Helmerich & Payne (HP) upgraded to Overweight from Equal Weight at Stephens... Himax (HIMX) upgraded to Outperform from Neutral at Credit Suisse... Huntington Bancshares (HBAN) upgraded to Buy from Neutral at Guggenheim... InterContinental (IHG) upgraded to Outperform from Neutral at Credit Suisse... Knight Transportation (KNX) upgraded to Strong Buy on valuation at Raymond James... LogMeln (LOGM) upgraded to Overweight from Sector Weight at Pacific Crest... Patterson Companies (PDCO) upgraded to Overweight from Neutral at Piper Jaffray... Qunar (QUNR) upgraded on valuation, positive catalysts at Stifel... Regions Financial (RF) upgraded to Buy from Neutral at Guggenheim... Ryder (R) upgraded to Strong Buy from Outperform at Raymond James... SVB Financial (SIVB) upgraded to Buy from Neutral at DA Davidson... Seagate (STX) upgraded to Buy from Hold at Cross Research... Sinopec (SNP) upgraded to Neutral from Sell at Citi... Summit Hotel Properties (INN) upgraded to Outperform at Baird... Texas Capital (TCBI) upgraded to Buy from Neutral at DA Davidson... The Medicines Co. (MDCO) upgraded to Buy from Hold at Jefferies... U.S. Bancorp (USB) upgraded to Buy from Neutral at Guggenheim... Weatherford (WFT) upgraded to Overweight from Equal Weight at Stephens.
07:59 EDTBMYBristol-Myers management to meet with Leerink
Subscribe for More Information
06:35 EDTMDCOThe Medicines Co. upgraded to Buy from Hold at Jefferies
Jefferies upgraded The Medicines Co. to Buy and increased its price target to $43 from $29. The firm said company has multiple data readouts for pipeline assets over the next 12-18 months starting with PI data from ALN-PCSsc in patients with elevated LDL on Sunday morning. Jefferies also highlighted the ongoing TANGO 1 trial comparing Carbavance to piperacillin-tazobactam in 850 patients with complicated urinary tract infection with data expected in mid-2016 that should also support its thesis.
August 27, 2015
10:35 EDTBMYBristol-Myers calls active
Bristol-Myers August weekly 61 and 61.5 calls are active on total call volume of 7K contracts (4K puts). August weekly call option implied volatility is at 35, September is at 34, October is at 28; compared to its 52-week range of 14 to 36. Active call volume suggests traders taking positions for price movement.
07:51 EDTBMYRoche catching up fast to Bristol-Myers in immuno-oncology, says Jefferies
Subscribe for More Information
05:28 EDTBMYAllied-Bristol Life Sciences announces licensing agreement with Yale University
Subscribe for More Information
August 24, 2015
11:43 EDTMDCOThe Medicines Co. and Alnylam Pharmaceuticals hold a joint conference call
Subscribe for More Information
09:45 EDTBMYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Bank of America (BAC) upgraded to Outperform from Market Perform at Keefe Bruyette... Bristol-Myers (BMY) upgraded to Neutral from Underweight at Piper Jaffray... Chevron (CVX) upgraded to Neutral from Underperform at BofA/Merrill... Abercrombie & Fitch (ANF) upgraded to Overweight from Neutral... Nike (NKE) upgraded to Outperform from Market Perform at Telsey Advisory... DreamWorks (DWA) upgraded to Buy from Neutral at B. Riley... Caesarstone (CSTE) upgraded to Overweight from Equal Weight at Barclays... TransAlta (TAC) upgraded to Outperform from Market Perform at BMO Capital... Sarepta (SRPT) upgraded to Overweight from Neutral at Piper Jaffray... AutoZone (AZO) upgraded to Buy from Neutral at BofA/Merrill... Royal Dutch Shell (RDS.A) upgraded to Buy from Hold at Jefferies... Allscripts (MDRX) upgraded to Buy from Hold at Argus... China Unicom (CHU) upgraded to Buy from Hold at Jefferies... Ross Stores (ROST) upgraded to Buy from Neutral at Buckingham.
08:16 EDTBMYBristol-Myers, Pfizer to present new data on Eliquis at ESC Congress 2015
Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) announced that 22 abstracts will be presented at the ESC Congress 2015, to be held August 29 to September 2 in London, United Kingdom. The new data reinforce the Alliance's commitment to the ongoing evaluation of Eliquis in both the nonvalvular atrial fibrillation and venous thromboembolism patient populations. In addition, data from the AEGEAN study evaluating adherence among NVAF patients further extends the Alliance's commitment to patient care.
07:08 EDTBMYBristol-Myers upgraded to Neutral from Underweight at Piper Jaffray
Subscribe for More Information
August 23, 2015
12:35 EDTBMYBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use